LY2189265 and Lifestyle Measures; Placebo solution and Lifestyle Measures
Проводит Эли Лилли энд Компани
Страница компанииAssessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00791479/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 167 чел. во всех странах исследования.
- Плановая дата окончания (01.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Индекс массы тела23–40 кг/м²
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 24
Критерии включения
- Diabetes mellitus, type 2
- Treatment regimens: diet and exercise only or are taking metformin as monotherapy and are willing to discontinue this medication
- Have completed at least 8 weeks of wash-out prior to randomization (if on metformin therapy at screening)
- Have a qualifying glycosylated hemoglobin (HbA1c) value, as determined by the central laboratory: at screening (for diet and exercise only ≥7.0% to ≤9.5%; for metformin monotherapy >6.5% to ≤9.0%) and at time of randomization for all participants ≥6.5% to ≤9.5%
- Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method
- Have a body mass index (BMI) between 23 and 40 kilograms/meter squared (kg/m\^2), inclusive, for participants who are native to, and reside in, South and/or East Asia; all other participants must have a BMI between 25 and 40 kg/m\^2, inclusive.
- Stable weight for 3 months prior to screening
Критерии невключения
- Diabetes mellitus, type 1
- Taking any glucose-lowering oral agents other than metformin within 3 months prior to screening
- Use of glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or being treated within insulin (with the exception of short-term management of acute conditions that occurred more than 3 months immediately prior to screening)
- Use of medications (prescription or over-the counter) to promote weight loss
- Chronic (>2 weeks) use of systemic glucocorticoid therapy
- Gastric emptying abnormality, history of bariatric surgery or chronic use of drugs that affect gastrointestinal motility
- Use of central nervous system (CNS) stimulant (for example, Ritalin-sustained release \[SR\])
- Cardiovascular event within 6 months prior to screening
- Poorly controlled hypertension (determined by a mean seated systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or mean seated diastolic BP ≥95 mmHg at screening or randomization)
- Electrocardiogram (ECG) reading considered outside the normal limits by the investigator and relevant for interpretation or indicating cardiac disease
- Liver disease, hepatitis, chronic hepatitis, or alanine transaminase levels >3.0 times upper limit of normal
- Clinical signs or symptoms of pancreatitis or history of chronic or acute pancreatitis at time of screening
- Amylase ≥3 times the upper limit of normal and/or lipase ≥2 times upper limit of normal which are determined by central labs at the time of screening
- Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) for men or ≥1.4 mg/dL for women or a creatinine clearance <60 milliliter (mL)/minute which are determined by central labs at the time of screening
- Uncontrolled diabetes (defined as 2 or more episode of hyperosmolar state requiring hospitalization in the 6 months prior to screening)
- Significant active, uncontrolled endocrine or autoimmune abnormality
- History of a transplanted organ (corneal transplants are allowed)
- Active or untreated malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
- Have any other condition, in the opinion of the investigator, that may preclude the participant from following or completing the protocol
- Investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling, whether biological or legally adopted)
- Sponsor employees
- Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to entry into the study
- Have previously completed or withdrawn from this study after providing informed consent
Источник: ClinicalTrials.gov, NCT00791479 · запись обновлена в реестре 10 декабря 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 16
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) — Baseline, 12 weeks
Цель исследования
This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00791479 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.